Olpasiran
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elevated Serum Lipoprotein(a)
Conditions
Elevated Serum Lipoprotein(a)
Trial Timeline
Jul 28, 2021 → Mar 18, 2022
NCT ID
NCT04987320About Olpasiran
Olpasiran is a phase 1 stage product being developed by Amgen for Elevated Serum Lipoprotein(a). The current trial status is completed. This product is registered under clinical trial identifier NCT04987320. Target conditions include Elevated Serum Lipoprotein(a).
What happened to similar drugs?
0 of 4 similar drugs in Elevated Serum Lipoprotein(a) were approved
Approved (0) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07079267 | Pre-clinical | Active |
| NCT05489614 | Phase 1 | Completed |
| NCT05481411 | Phase 1 | Completed |
| NCT04987320 | Phase 1 | Completed |
Competing Products
12 competing products in Elevated Serum Lipoprotein(a)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Muvalaplin + Placebo | Eli Lilly | Phase 3 | 47 |
| Baricitinib | Eli Lilly | Pre-clinical | 26 |
| Rosuvastatin | AstraZeneca | Phase 3 | 32 |
| TQJ230 + Placebo | Novartis | Phase 3 | 44 |
| LIK066 + Placebo | Novartis | Phase 2 | 35 |
| Maridebart cafraglutide + Placebo | Amgen | Phase 2 | 42 |
| Ivabradine | Amgen | Phase 3 | 32 |
| ALN-PCS02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 26 |
| ISIS-APO(a)Rx + Placebo | Ionis Pharmaceuticals | Phase 2 | 32 |
| APOC-III-L-Rx + Placebo Comparator | Ionis Pharmaceuticals | Phase 1 | 26 |
| ISIS 681257 + Placebo | Ionis Pharmaceuticals | Phase 2 | 32 |
| IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl) | Ionis Pharmaceuticals | Phase 1 | 26 |